Literature DB >> 20966765

Mitochondria-targeted cardioprotection in aldosteronism.

Atta U Shahbaz1, German Kamalov, Wenyuan Zhao, Tieqiang Zhao, Patti L Johnson, Yao Sun, Syamal K Bhattacharya, Robert A Ahokas, Ivan C Gerling, Karl T Weber.   

Abstract

Chronic aldosterone/salt treatment (ALDOST) is accompanied by an adverse structural remodeling of myocardium that includes multiple foci of microscopic scarring representing morphologic footprints of cardiomyocyte necrosis. Our previous studies suggested that signal-transducer-effector pathway leading to necrotic cell death during ALDOST includes intramitochondrial Ca overloading, together with an induction of oxidative stress and opening of the mitochondrial permeability transition pore (mPTP). To further validate this concept, we hypothesized that mitochondria-targeted interventions will prove to be cardioprotective. Accordingly, 8-week-old male Sprague-Dawley rats receiving 4 weeks ALDOST were cotreated with either quercetin, a flavonoid with mitochondrial antioxidant properties, or cyclosporine A (CsA), an mPTP inhibitor, and compared with ALDOST alone or untreated, age/sex-matched controls. We monitored mitochondrial free Ca and biomarkers of oxidative stress, including 8-isoprostane and H2O2 production; mPTP opening; total Ca in cardiac tissue; and collagen volume fraction to quantify replacement fibrosis, a biomarker of cardiomyocyte necrosis, and employed terminal deoxynucleotidyl transferase dUTP nick end labeling assay to address apoptosis in coronal sections of ventricular myocardium. Compared with controls, at 4 weeks ALDOST we found a marked increase in mitochondrial H2O2 production and 8-isoprostane levels, an increased propensity for mPTP opening, and greater concentrations of mitochondrial free [Ca]m and total tissue Ca, coupled with a 5-fold rise in collagen volume fraction without any terminal deoxynucleotidyl transferase dUTP nick end labeling-based evidence of cardiomyocyte apoptosis. Each of these pathophysiologic responses to ALDOST was prevented by quercetin or cyclosporine A cotreatment. Thus, mitochondria play a central role in initiating the cellular-subcellular mechanisms that lead to necrotic cell death and myocardial scarring. This destructive cycle can be interrupted and myocardium salvaged with its structure preserved by mitochondria-targeted cardioprotective strategies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20966765      PMCID: PMC3022960          DOI: 10.1097/FJC.0b013e3181fe1250

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  45 in total

1.  Aldosterone-induced inflammation in the rat heart : role of oxidative stress.

Authors:  Yao Sun; Jiakun Zhang; Li Lu; Sue S Chen; Mark T Quinn; Karl T Weber
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

2.  Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin.

Authors:  Paul S Brookes; Stanley B Digerness; Dale A Parks; Victor Darley-Usmar
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

Review 3.  Calcineurin and hypertrophic heart disease: novel insights and remaining questions.

Authors:  Orlando F Bueno; Eva van Rooij; Jeffery D Molkentin; Pieter A Doevendans; Leon J De Windt
Journal:  Cardiovasc Res       Date:  2002-03       Impact factor: 10.787

Review 4.  Mitochondria and calcium: from cell signalling to cell death.

Authors:  M R Duchen
Journal:  J Physiol       Date:  2000-11-15       Impact factor: 5.182

5.  Uncoupling the coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria seen in aldosteronism.

Authors:  German Kamalov; Robert A Ahokas; Wenyuan Zhao; Tieqiang Zhao; Atta U Shahbaz; Patti L Johnson; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2010-03       Impact factor: 3.105

6.  Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Authors:  Benjamin J Wilkins; Yan-Shan Dai; Orlando F Bueno; Stephanie A Parsons; Jian Xu; David M Plank; Fred Jones; Thomas R Kimball; Jeffery D Molkentin
Journal:  Circ Res       Date:  2003-12-01       Impact factor: 17.367

7.  Sanglifehrin A acts as a potent inhibitor of the mitochondrial permeability transition and reperfusion injury of the heart by binding to cyclophilin-D at a different site from cyclosporin A.

Authors:  Samantha J Clarke; Gavin P McStay; Andrew P Halestrap
Journal:  J Biol Chem       Date:  2002-07-02       Impact factor: 5.157

Review 8.  Cyclophilin D as a drug target.

Authors:  Peter C Waldmeier; Kaspar Zimmermann; Ting Qian; Marina Tintelnot-Blomley; John J Lemasters
Journal:  Curr Med Chem       Date:  2003-08       Impact factor: 4.530

9.  Mitochondrial oxidative stress and cell death in astrocytes--requirement for stored Ca2+ and sustained opening of the permeability transition pore.

Authors:  Jake Jacobson; Michael R Duchen
Journal:  J Cell Sci       Date:  2002-03-15       Impact factor: 5.285

Review 10.  Ca(2+) signalling in mitochondria: mechanism and role in physiology and pathology.

Authors:  Marisa Brini
Journal:  Cell Calcium       Date:  2003 Oct-Nov       Impact factor: 6.817

View more
  16 in total

Review 1.  Disturbances in calcium metabolism and cardiomyocyte necrosis: the role of calcitropic hormones.

Authors:  Jawwad Yusuf; M Usman Khan; Yaser Cheema; Syamal K Bhattacharya; Karl T Weber
Journal:  Prog Cardiovasc Dis       Date:  2012 Jul-Aug       Impact factor: 8.194

2.  Reverse remodeling and recovery from cachexia in rats with aldosteronism.

Authors:  Yaser Cheema; Wenyuan Zhao; Tieqiang Zhao; M Usman Khan; Kelly D Green; Robert A Ahokas; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-06-22       Impact factor: 4.733

3.  Small dedifferentiated cardiomyocytes bordering on microdomains of fibrosis: evidence for reverse remodeling with assisted recovery.

Authors:  Fahed Al Darazi; Wenyuan Zhao; Tieqiang Zhao; Yao Sun; Tony N Marion; Robert A Ahokas; Syamal K Bhattacharya; Ivan C Gerling; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2014-09       Impact factor: 3.105

Review 4.  Role of oxidative stress in disease progression in Stage B, a pre-cursor of heart failure.

Authors:  Arvind Bhimaraj; W H Wilson Tang
Journal:  Heart Fail Clin       Date:  2011-10-22       Impact factor: 3.179

5.  Intracellular calcium overloading and oxidative stress in cardiomyocyte necrosis via a mitochondriocentric signal-transducer-effector pathway.

Authors:  Mazen Shaheen; Yaser Cheema; Atta U Shahbaz; Syamal K Bhattacharya; Karl T Weber
Journal:  Exp Clin Cardiol       Date:  2011

6.  Phosphoproteome mapping of cardiomyocyte mitochondria in a rat model of heart failure.

Authors:  Francesco Giorgianni; M Usman Khan; Karl T Weber; Ivan C Gerling; Sarka Beranova-Giorgianni
Journal:  Mol Cell Biochem       Date:  2014-01-07       Impact factor: 3.396

7.  Mitochondriocentric pathway to cardiomyocyte necrosis in aldosteronism: cardioprotective responses to carvedilol and nebivolol.

Authors:  Yaser Cheema; Jonathan N Sherrod; Wenyuan Zhao; Tieqiang Zhao; Robert A Ahokas; Yao Sun; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2011-07       Impact factor: 3.105

Review 8.  Myofibroblast-mediated mechanisms of pathological remodelling of the heart.

Authors:  Karl T Weber; Yao Sun; Syamal K Bhattacharya; Robert A Ahokas; Ivan C Gerling
Journal:  Nat Rev Cardiol       Date:  2012-12-04       Impact factor: 32.419

Review 9.  Myofibroblast secretome and its auto-/paracrine signaling.

Authors:  Ritin Bomb; Mark R Heckle; Yao Sun; Salvatore Mancarella; Ramareddy V Guntaka; Ivan C Gerling; Karl T Weber
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-02-17

10.  Atrophic cardiomyocyte signaling in hypertensive heart disease.

Authors:  German Kamalov; Wenyuan Zhao; Tieqiang Zhao; Yao Sun; Robert A Ahokas; Tony N Marion; Fahed Al Darazi; Ivan C Gerling; Syamal K Bhattacharya; Karl T Weber
Journal:  J Cardiovasc Pharmacol       Date:  2013-12       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.